Jeffrey W. Sherman

Jeffrey W. Sherman is a declared insider at 4 companies (senior executive); the most frequent names are Horizon Therapeutics Public Ltd Co, Xeris Biopharma Holdings, Inc. and Strongbridge Biopharma plc. We count 30 filings; the first trade dates from 2 January 2016 and the latest from 27 February 2026.

Market trades split into 2 purchases (€30k) and 2 sales (€4.6M). On balance, insiders were net sellers of €4.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 10 share grants and 6 option exercises. So far in 2026, the count stands at 1 purchase and no sales.

The record was last updated on 2 March 2026 with an open-market purchase (€21k) in Larimar Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.